Trials / Completed
CompletedNCT02594865
The Glycaemic Effects of Glucerna® in Critically Ill Patients.
Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- PHJ van der Voort · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether the administration of Glucerna achieves less glycaemic variability, defined as the mean absolute glucose (MAG) change, and better glycaemic control compared to a standard high-carbohydrate enteral formula. Continuous glucose monitoring technology will be used to evaluate glycaemic variability and glycaemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Glucerna | Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding. |
| DIETARY_SUPPLEMENT | Fresubin | Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding. |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2015-11-03
- Last updated
- 2016-06-27
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02594865. Inclusion in this directory is not an endorsement.